Seasonal Trends in Palivizumab Compliance in High-Risk Infants Before, During, and After COVID-19 Restrictions

Read full text Summarise with VIRAT
Authors: Batuhan Yeke
Cited by: 0
References: 1

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aim: This study aimed to evaluate compliance with palivizumab prophylaxis in high-risk infants before and after the COVID-19 pandemic and to assess its effect on RSV and other respiratory infections. Materials and Methods: This retrospective observational study included 626 high-risk infants who received at least one dose of palivizumab at Ankara Bilkent City Hospital’s NICU between October 2019 and April 2023. Compliance was assessed by evaluating whether doses were administered at 30 ± 5-day intervals. Infants receiving all scheduled doses were classified as full prophylaxis (n=548, 87.5%), while those missing at least one dose were classified as partial prophylaxis (n=78, 12.5%). RSV and non-RSV infection and hospitalization rates were compared. Data were obtained from hospital records and interviews with parents. Results: While 87.5% received full prophylaxis, only 65.2% followed the recommended dosing intervals. Partial compliance was mostly due to family neglect or hospitalization. RSV infections occurred more frequently in the partial group (9% vs. 4.6%), though the difference was not statistically significant. Non-RSV pneumonia and bronchiolitis rates were significantly higher in partially compliant infants (p

Fields of Study & Subjects

Respiratory viral infections research Pediatric health and respiratory diseases Pneumonia and Respiratory Infections

Publication details

Journal / source
Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
Volume
23
Issue
1
Pages
14–21
Publication date
31 March 2026
Language
TR